Replies to post #59342 on Biotech Values

[Bio_pete]

ENCY was forecasting $40 - $50 million in sales for 2008 so maybe thats how he gets the 4X number. The $100 million peak sales number in 2012 seems low if it includes the US market.

[DewDiligence]

PFE is assuming ENCY’s liabilities, which total about $200M. This brings the effective deal price to about $350M after adjusting for ENCY’s cash on hand.

[DewDiligence]

PFE pulls Thelin from worldwide markets:

http://finance.yahoo.com/news/Pfizer-Stops-Clinical-Trials-prnews-988327990.html?x=0&.v=1

There goes the purported value of the 2008 ENCY acquisition.